Back to top

Image: Bigstock

How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?

Read MoreHide Full Article

Key Takeaways

  • Pfizer's oncology segment is expected to post $4 billion in Q2 sales.
  • PFE's ADC products show mixed trends, with Padcev sales rising and Adcetris hit by U.S. competition.
  • Ibrance sales likely declined due to competition, generics and IRA-driven pricing pressure.

Pfizer (PFE - Free Report) is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, Tukysa and Tivdak — to the company’s portfolio. In first-quarter 2025, oncology contributed more than 25% to Pfizer’s total revenues, growing 7% year over year. Investors will be closely watching this segment when Pfizer reports second-quarter results on Aug. 5.

Within the oncology unit, sales of Xtandi, Lorbrena and Braftovi/Mektovi are likely to have increased during the quarter. However, sales of key medicine Ibrance are expected to have been hurt due to continued competitive pressure across markets, generic entry and the Inflation Reduction Act ("IRA") impact in the United States.

With regard to ADC products, competitive pressure in the United States is likely to have hurt sales of Adcetris, while strong demand trends must have benefited Padcev’s sales.

Our model estimates for second-quarter 2025 sales of the overall oncology segment are pegged at $4.0 billion, implying a 2% rise year over year.

Beyond oncology, Pfizer’s top line is likely to have been aided by its key in-line products like Vyndaqel and Eliquis, alongside newer additions like Nurtec. However, this growth is expected to have been offset by the U.S. Medicare Part D headwinds and the continued declining sales of its COVID-19 products.

Competition in the Oncology Space

Other large players in the oncology space are AstraZeneca (AZN - Free Report) and Merck (MRK - Free Report) .

For AstraZeneca, oncology sales now account for nearly 41% of total revenues. Sales in its oncology segment rose 13% in the first quarter of 2025. AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).

Merck’s key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounted for more than 46% of Merck’s total revenues in the first quarter of 2025.

PFE’s Price Performance, Valuation and Estimates

Shares of Pfizer have underperformed the industry year to date, as shown in the chart below.

Zacks Investment Research
Image Source: Zacks Investment Research

From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company’s shares currently trade at 8.25 times forward earnings, lower than 15.12 for the industry and the stock’s 5-year mean of 10.86.

Zacks Investment Research
Image Source: Zacks Investment Research

The bottom-line estimate for 2025 has declined from $3.08 to $3.05, while that for 2026 has gone up from $3.08 to $3.09 over the past 60 days.

Zacks Investment Research
Image Source: Zacks Investment Research

Pfizer currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


AstraZeneca PLC (AZN) - free report >>

Pfizer Inc. (PFE) - free report >>

Merck & Co., Inc. (MRK) - free report >>

Published in